<?xml version='1.0' encoding='utf-8'?>
<document id="27169677"><sentence text="Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report."><entity charOffset="22-31" id="DDI-PubMed.27169677.s1.e0" text="tamoxifen" /><entity charOffset="100-108" id="DDI-PubMed.27169677.s1.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.27169677.s1.e0" e2="DDI-PubMed.27169677.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27169677.s1.e0" e2="DDI-PubMed.27169677.s1.e1" /></sentence><sentence text="Tamoxifen, a common anti-estrogen breast cancer medication, is a prodrug that undergoes bioactivation via cytochrome P450 enzymes, CYP2D6 and to a lesser degree, CYP3A4 to form the active metabolite endoxifen"><entity charOffset="0-9" id="DDI-PubMed.27169677.s2.e0" text="Tamoxifen" /></sentence><sentence text=" With an increasing use of oral anti-cancer drugs, the risk for drug-drug interactions mediated by enzyme inhibitors and inducers may also be expected to increase" /><sentence text=" Here we report the first case demonstrating a potent drug-drug interaction in a real-world clinical setting between tamoxifen and rifampin in a breast cancer patient being treated concurrently for ulcerative colitis"><entity charOffset="117-126" id="DDI-PubMed.27169677.s4.e0" text="tamoxifen" /><entity charOffset="131-139" id="DDI-PubMed.27169677.s4.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.27169677.s4.e0" e2="DDI-PubMed.27169677.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27169677.s4.e0" e2="DDI-PubMed.27169677.s4.e1" /></sentence><sentence text="" /><sentence text="We describe a patient on adjuvant tamoxifen therapy for breast cancer that was prescribed rifampin for TB prophylaxis prior to initiation of an anti-tumor necrosis factor (TNF)-α agent due to worsening ulcerative colitis"><entity charOffset="34-43" id="DDI-PubMed.27169677.s6.e0" text="tamoxifen" /><entity charOffset="90-98" id="DDI-PubMed.27169677.s6.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.27169677.s6.e0" e2="DDI-PubMed.27169677.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27169677.s6.e0" e2="DDI-PubMed.27169677.s6.e1" /></sentence><sentence text=" This 39 year old Caucasian woman had been followed by our personalized medicine clinic where CYP2D6 genotyping and therapeutic monitoring of tamoxifen and endoxifen levels had been carried out"><entity charOffset="142-151" id="DDI-PubMed.27169677.s7.e0" text="tamoxifen" /><entity charOffset="156-165" id="DDI-PubMed.27169677.s7.e1" text="endoxifen" /><pair ddi="false" e1="DDI-PubMed.27169677.s7.e0" e2="DDI-PubMed.27169677.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27169677.s7.e0" e2="DDI-PubMed.27169677.s7.e1" /></sentence><sentence text=" The patient, known to be a CYP2D6 intermediate metabolizer, had a previous history of therapeutic endoxifen levels" /><sentence text=" Upon admission to hospital for a major flare of her ulcerative colitis a clinical decision was made to initiate an anti-TNFα biological agent" /><sentence text=" Due to concerns regarding latent TB, rifampin as an anti-mycobacterial agent was initiated which the patient was only able tolerate for 10 days"><entity charOffset="38-46" id="DDI-PubMed.27169677.s10.e0" text="rifampin" /></sentence><sentence text=" Interestingly, her plasma endoxifen concentration measured 2 weeks after cessation of rifampin was sub-therapeutic at 15"><entity charOffset="87-95" id="DDI-PubMed.27169677.s11.e0" text="rifampin" /></sentence><sentence text="8 nM and well below her previous endoxifen levels which exceeded 40 nM" /><sentence text="" /><sentence text="Rifampin should be avoided in patients on tamoxifen therapy for breast cancer unless continued tamoxifen efficacy can be assured through endoxifen monitoring"><entity charOffset="0-8" id="DDI-PubMed.27169677.s14.e0" text="Rifampin" /><entity charOffset="42-51" id="DDI-PubMed.27169677.s14.e1" text="tamoxifen" /><entity charOffset="95-104" id="DDI-PubMed.27169677.s14.e2" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.27169677.s14.e0" e2="DDI-PubMed.27169677.s14.e0" /><pair ddi="false" e1="DDI-PubMed.27169677.s14.e0" e2="DDI-PubMed.27169677.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27169677.s14.e0" e2="DDI-PubMed.27169677.s14.e2" /><pair ddi="false" e1="DDI-PubMed.27169677.s14.e1" e2="DDI-PubMed.27169677.s14.e1" /><pair ddi="false" e1="DDI-PubMed.27169677.s14.e1" e2="DDI-PubMed.27169677.s14.e2" /></sentence><sentence text=" Drug-drug interactions can pose a significant risk of sub-therapeutic benefit in tamoxifen patients"><entity charOffset="82-91" id="DDI-PubMed.27169677.s15.e0" text="tamoxifen" /></sentence><sentence text="" /></document>